Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer.
Ichihashi A, Inamoto T, Uchimoto T, Nakamura KO, Komura K, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Yamamoto K, Kato R, Ijiri Y, Hayashi T, Azuma H. Ichihashi A, et al. Among authors: inamoto t. In Vivo. 2023 Jan-Feb;37(1):143-148. doi: 10.21873/invivo.13063. In Vivo. 2023. PMID: 36593015 Free PMC article.
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Yano Y, Ohno T, Komura K, Fukuokaya W, Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Yamazaki S, Tokushige S, Nishimura K, Tsujino T, Nakamori K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Yano Y, et al. Among authors: inamoto t. Cancers (Basel). 2022 Nov 17;14(22):5659. doi: 10.3390/cancers14225659. Cancers (Basel). 2022. PMID: 36428750 Free PMC article.
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.
Nakamori K, Yamazaki S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Ohno T, Yano Y, Nishimura K, Tokushige S, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Nakamori K, et al. Among authors: inamoto t. Clin Transl Radiat Oncol. 2022 Dec 10;39:100558. doi: 10.1016/j.ctro.2022.12.001. eCollection 2023 Mar. Clin Transl Radiat Oncol. 2022. PMID: 36545361 Free PMC article.
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
Sato R, Inamoto T, Matsushita Y, Takemura A, Uchimoto T, Sano A, Tanaka H, Ishikawa G, Watanabe K, Watanabe H, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Harada KI, Azuma H, Miyake H. Sato R, et al. Among authors: inamoto t. Int J Urol. 2023 Sep;30(9):730-736. doi: 10.1111/iju.15133. Epub 2022 Dec 27. Int J Urol. 2023. PMID: 36575640
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, Nishimura K, Yano Y, Nishio K, Kinoshita S, Fukushima T, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Miyake H, Azuma H. Inamoto T, et al. Cancer Diagn Progn. 2023 May 3;3(3):370-376. doi: 10.21873/cdp.10226. eCollection 2023 May-Jun. Cancer Diagn Progn. 2023. PMID: 37168961 Free PMC article.
Usefulness of Dietary Salt Restriction in Kidney Transplant Recipients: Analysis of Blood Pressure Levels Depending on the Differences in the Levels of Salt Intake.
Hirano H, Fujiwara Y, Maenosono R, Minami K, Uehara H, Okabe T, Nakamori K, Nomi H, Komura K, Inamoto T, Azuma H. Hirano H, et al. Among authors: inamoto t. Transplant Proc. 2023 May;55(4):841-844. doi: 10.1016/j.transproceed.2023.03.054. Epub 2023 May 10. Transplant Proc. 2023. PMID: 37169600 Free article.
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: inamoto t. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Komura K, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, Ajiro M, Ohno T, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: inamoto t. Cancer Sci. 2023 Dec;114(12):4622-4631. doi: 10.1111/cas.15976. Epub 2023 Sep 26. Cancer Sci. 2023. PMID: 37752769 Free PMC article.
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.
Nishio K, Higashio T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Tsuchida S, Matsuda T, Tsujino T, Nishimura K, Tokushige S, Nakamori K, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Nishio K, et al. Among authors: inamoto t. Oncology. 2024;102(6):457-464. doi: 10.1159/000534554. Epub 2023 Oct 13. Oncology. 2024. PMID: 37839399
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Nukaya T, Takahara K, Yoshizawa A, Saruta M, Yano Y, Ohno T, Uchimoto T, Fukuokaya W, Adachi T, Yamazaki S, Tokushige S, Nishimura K, Tsujino T, Nakamori K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Hirasawa Y, Hashimoto T, Komura K, Inamoto T, Miki J, Kimura T, Ohno Y, Azuma H, Shiroki R. Nukaya T, et al. Among authors: inamoto t. Clin Genitourin Cancer. 2024 Feb;22(1):76-83. doi: 10.1016/j.clgc.2023.09.007. Epub 2023 Oct 1. Clin Genitourin Cancer. 2024. PMID: 37880020
340 results